TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07022483: A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

Sponsor: Daiichi Sankyo · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 710 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07022483 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07022483 Rescue Dossier →